All In Biotech

Drug Trial Radar · NCT01288027

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Last checked: Nov 20, 2026Latest source record: Dec 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jun 2011

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study of participants with late-onset Pompe disease naive to treatment with enzyme replacement therapy (ERT). The primary objective of this study is to evaluate glycogen clearance in muscle tissue samples collected pre and post alglucosidase alfa treatment in participants with Late-Onset Pompe disease. The secondary objectives are to characterize the disease burden in participants with late-onset Pompe disease and explore imaging, histologic, and functional assessments in these participants and to explore potential plasma or urine biomarkers relative to late-onset Pompe disease and participant's response to treatment with alglucosidase alfa (Myozyme®/Lumizyme®/GZ419829).

Conditions

  • Pompe Disease (Late-Onset)
  • Glycogen Storage Disease Type II (GSD II)
  • Glycogenesis 2 Acid Maltase Deficiency

Interventions

  • Alglucosidase AlfaBiological

    Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Tissue Glycogen Content in Quadriceps Muscle Biopsy Samples at Week 26Time frame: Baseline, Week 26

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Orange, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Kansas City, Kansas

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Colombus, Ohio

  • Site not named

    Heshey, Pennsylvania

  • Site not named

    Fairfax, Virginia

  • Site not named

    Mainz, Germany

  • Site not named

    München, Germany

  • Site not named

    Münster, Germany

  • Site not named

    Rotterdam, Netherlands

  • Site not named

    Newcastle upon Tyne, United Kingdom

  • Site not named

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.